TL;DR
Forty years of Russian data. One 2003 telomere paper. Almost zero Western replication.
What is it? A four-amino-acid peptide (Ala-Glu-Asp-Gly) extracted from cow pineal gland. Developed in Vladimir Khavinson's St. Petersburg institute starting in the 1970s.
What does it do? A 2003 paper showed it switches telomerase back on in cultured human cells. Animal studies show restored melatonin, cleaner blood markers, reduced spontaneous tumors in aged mice.
Does the evidence hold up? Partially. The telomere claim was replicated independently in 2025. But the 266-patient mortality data — 1.6 to 4.1× fewer deaths over 6–8 years — lives inside one Russian lab and hasn't been rerun at Western trial standard.
Who uses it? Russian geriatric clinics for 30+ years. Longevity enthusiasts running 10-day courses twice a year.
Bottom line? The biggest longevity dataset nobody has replicated. Weigh accordingly.
What It Is
Epithalon (also spelled Epitalon, and referred to as AEDG after its amino acid code) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It is the best-known member of the "Khavinson bioregulators" — a family of short peptides developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s–80s. The research program's guiding hypothesis was that short peptides derived from fractionated tissue extracts ("bioregulators") could normalize tissue-specific function in aged or damaged organs. Epithalon specifically was derived from the bovine pineal gland extract Epithalamin, isolated, sequenced, and reduced to its minimal biologically active tetrapeptide.
What makes Epithalon one of the most-discussed longevity peptides is a single 2003 paper: Khavinson, Bondarev, and Butyugov in Bulletin of Experimental Biology and Medicine (PMID 12937682) reported that Epithalon activated telomerase and elongated telomeres in cultured human somatic cells. That finding — directly linking a short synthetic peptide to one of the central mechanisms of cellular aging (telomere attrition) — made Epithalon the most-cited "anti-aging peptide" in community longevity discussions and generated decades of commercial and experiential use.
The broader Epithalon / Epithalamin evidence base includes multiple clinical observational cohort studies from the Khavinson group reporting reduced mortality in elderly patients over 6–8 years of follow-up, particularly when combined with thymalin (the thymic peptide bioregulator). These are among the longest-duration human intervention studies in the entire peptide-longevity space. They are also methodologically heterogeneous, Russian-language-dominant, and have never been replicated at Western Phase 3 regulatory standard. That methodological gap is the central tension of the Epithalon evidence profile.
In the Kalios context, Epithalon sits in the "longevity peptide" category alongside Pinealon, Thymalin, NAD+, and similar bioregulator-class compounds. It is off-label, gray-market sourced, and not FDA-approved. Community use is primarily in longevity protocols of 10–20 day courses repeated 1–2× per year. Individual response is highly variable, and the subjective endpoints (energy, sleep, sense of well-being) are hard to separate from placebo in an uncontrolled setting.
Mechanism of Action
Epithalon's proposed mechanisms extend beyond the headline telomerase activation claim. The following synthesizes the Khavinson group's framework and independent molecular biology literature.
- Telomerase activation (hTERT expression) — The flagship mechanism. Khavinson et al. (2003; PMID 12937682) reported that Epithalon activates telomerase in cultured human somatic cells. Al-Dulaimi et al. 2025 (PMID 40908429) extended this, showing Epithalon increases telomere length in human cell lines through both telomerase upregulation and ALT (alternative lengthening of telomeres) activity — a modern, independent replication of the central claim.
- Gene expression modulation (proposed DNA binding) — Khavinson's group has proposed that short peptides like Epithalon bind specific DNA sequences and modulate gene expression at the transcriptional level. This hypothesis — short-peptide direct DNA binding as a regulatory mechanism — is unusual and has been received skeptically in mainstream molecular biology; some in-vitro support exists.
- Pineal gland / melatonin axis — Epithalon normalizes age-related decline of pineal melatonin output in animal models. This is the mechanistic link back to Epithalamin (the pineal extract from which Epithalon is derived). Restored melatonin rhythms contribute to improved circadian and sleep endpoints.
- Antioxidant / free radical modulation — Epithalon reduces oxidative stress markers and preserves antioxidant enzyme function in aged tissue models.
- Immune function — Preserves T-cell and NK-cell function in aged animals; synergistic with thymalin (thymic peptide) for immune restoration.
- Anti-tumor signaling — Reduced spontaneous tumor incidence in aged SHR mice (Anisimov et al., Biogerontology 2003). Mechanism hypothesized to involve improved tumor surveillance and reduced age-related immune decline rather than direct anti-tumor activity. Notably opposite direction from the theoretical cancer concern other telomerase-activating compounds raise.
- Circadian rhythm restoration — Restores age-disrupted circadian patterns in rodent models; plausibly mediated by pineal melatonin restoration.
- Retinal protection — Preserves photoreceptor function in retinitis pigmentosa and other retinal degeneration models.
- Plasma PK vs duration of effect — Epithalon has a very short plasma half-life (30 minutes) but clinical effects persist for weeks-to-months after a 10–20 day course. The gap is explained by the proposed gene-expression modulation: once transcriptional patterns are shifted, effects persist beyond drug clearance.
- Neuroprotection — Protective effects in models of neurodegeneration, particularly when given during the early disease course. Mechanism is multifactorial — antioxidant, circadian, immune.
What the Research Shows
The Epithalon evidence base is paradoxical: more long-duration human clinical data than almost any peptide in the community space, and less Western-methodology replication than most. Both are true.
- Telomerase activation (Khavinson, Bondarev, Butyugov 2003; PMID 12937682) — Foundational paper showing Epithalon induces telomerase activity and telomere elongation in human somatic cells in culture. The citation that launched modern community interest.
- SHR mice lifespan / tumor (Anisimov et al., Biogerontology 2003; PMID 14501183) — Female Swiss-derived SHR mice. Epithalon extended lifespan modestly and reduced spontaneous tumor incidence. Part of a broader Khavinson-group mouse longevity program.
- Elderly mortality (Khavinson cohort, Neuro Endocrinol Lett 2003; PMID 14523363) — 266 patients over age 60 followed 6–8 years. Epithalamin reduced 6-year mortality 1.6–1.8× vs control; combined with thymalin 2.5×; combined with thymalin + annual re-administration 4.1×. Among the largest long-duration peptide mortality data in the literature; methodologically prospective cohort rather than RCT.
- Retinitis pigmentosa (Khavinson 2002 open-label) — Open-label study reporting positive clinical effect in ~90% of treated retinitis pigmentosa patients. Small, uncontrolled.
- Cardiovascular disease elderly (Russian clinical series) — Multiple reports in elderly patients with cardiovascular and metabolic disease over 30+ years of clinical use.
- Telomere length in human cell lines (Al-Dulaimi et al., 2025; PMID 40908429) — Modern Western-lab replication showing Epithalon increases telomere length through both telomerase upregulation and ALT pathway activation. The most important recent independent validation of the central Khavinson telomere claim.
- Pineal melatonin restoration — Animal studies showing restoration of age-related pineal melatonin decline with Epithalon administration (Labunets 2004 and successors).
- Comprehensive modern review (Int J Mol Sci 2025) — "Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties" summarizing 40 years of research in a modern open-access format.
- Combined bioregulator protocols — The Khavinson group's clinical data consistently show Epithalon's largest benefits in combination with thymalin (thymic peptide) and/or prostatilen (prostate-derived peptide). Solo Epithalon effects are smaller.
- Absence of Phase 3 Western trial — No modern randomized placebo-controlled Phase 3 trial with Epithalon has been published in a Western regulatory framework. This is the central evidence gap.
Honest Evidence Framing
Epithalon has the single largest mortality-benefit dataset of any peptide in this database — the 266-person elderly cohort with 6–8 year follow-up and 1.6–4.1× mortality reduction vs control. It is also one of the peptides whose evidence is most concentrated in a single Russian research group, without the Western-methodology Phase 3 replication that would be required for FDA approval. Both observations are correct, and both matter. Community use is very common; mainstream Western clinical endocrinology does not recognize it as validated.
Human Data
Key human datasets:
- Khavinson elderly cohort (266 patients, 6–8 year follow-up) — Mortality reduction 1.6–4.1× depending on regimen. Prospective cohort, non-RCT. The single largest long-duration human peptide-longevity dataset.
- Russian clinical practice (30+ years) — Epithalon has been in clinical use in Russian geriatrics and ophthalmology for decades, accumulating an experiential evidence base.
- Retinitis pigmentosa open-label — ~90% response rate reported; small, uncontrolled.
- Cardiovascular / metabolic disease series — Multiple Russian clinical reports in elderly patients.
- Combined bioregulator regimens — Khavinson's protocols typically combine Epithalon with Thymalin for immune-longevity effects.
- Case reports (longevity / biological age) — Modern functional-medicine case reports describing biological-age marker improvement with Epithalon protocols.
- In-vitro telomerase replications — Al-Dulaimi 2025 provides independent modern confirmation of the Khavinson telomerase-activation claim.
- No modern Western Phase 3 — The gap that separates Epithalon from approved drugs.
The critical methodological point: Epithalon's human evidence is mostly long-duration observational cohort data from one research group. The biological-mechanism evidence (telomerase activation in cell lines) has independent replication. The clinical-outcome evidence (mortality reduction in elderly cohorts) has not been reproduced at Phase 3 level anywhere in the world.
Dosing from the Literature
The Khavinson protocols and community practice converge on short courses repeated periodically rather than continuous dosing.
| Protocol | Dose | Frequency | Notes |
|---|
| Khavinson elderly (injectable) | 10 mg | SubQ or IM daily × 10 days | 1–2 courses per year. The canonical "Khavinson protocol." |
| Community standard (SubQ) | 5–10 mg | Daily SubQ, 10–20 day course | Repeated 1–2× per year. Most common Western community pattern. |
| Low-dose daily (community) | 2–5 mg | Daily SubQ, 10–20 day course | Lower-dose variant; same course length. |
| Intranasal (community) | 5–10 mg | Daily IN, 10–20 day course | Less common; bioavailability less characterized. |
| Evening timing | — | Before bed | Aligns with presumed pineal-axis mechanism. Community preference. |
| Interval between courses | — | 6 months | Standard pattern: 10–20 days on, 6 months off, repeat. |
Dosing Disclaimer
Epithalon is not FDA-approved. There is no labeled human dose. The Khavinson protocols and community practice differ, and dose recommendations vary widely (2–10 mg/day, 10–20 day courses). Because Epithalon is a tetrapeptide with very short plasma half-life, continuous high-dose daily regimens have no mechanistic advantage over the pulse-dose courses the Khavinson framework uses.
Reconstitution & Storage
Epithalon is supplied as lyophilized powder, typically in 10 mg or 50 mg vials.
| Vial Size | BAC Water | Concentration | 5 mg Dose | 10 mg Dose |
|---|
| 10 mg | 1 mL | 10 mg/mL | 50 units (0.5 mL) | 100 units (1.0 mL) |
| 10 mg | 2 mL | 5 mg/mL | 100 units (1.0 mL) | Entire vial |
| 50 mg | 5 mL | 10 mg/mL | 50 units (0.5 mL) | 100 units (1.0 mL) |
| 50 mg | 2.5 mL | 20 mg/mL | 25 units (0.25 mL) | 50 units (0.5 mL) |
- Reconstitution — Inject BAC water slowly down the vial wall at 45°; swirl gently, never shake. Clear, colorless solution.
- Storage — Unreconstituted: 2–8°C preferred. Reconstituted: 2–8°C, use within 21–28 days. Do not freeze.
- Injection sites (SubQ) — Abdomen (2 inches from navel), thigh, or upper arm. Rotate sites during the 10–20 day course.
- Timing — Evening dosing is common community practice, aligning with pineal-melatonin mechanism rationale. No strong PK basis for timing preference.
- Intranasal alternative — Requires appropriate formulation / pH buffering; less commonly used than SubQ.
- Inspection — Discard if cloudy, discolored, or contaminated.
→ Use the Kalios Peptide Calculator for exact syringe units
Side Effects & Risks
Important
Epithalon has a clean safety record across 30+ years of Russian clinical use. Formal Western monitoring data doesn't exist. This is a doctor conversation.
Epithalon has a notably clean safety profile across 40+ years of Khavinson-group clinical use and community experience, though formal Western monitoring data are absent.
- Injection site reactions — Mild, transient; typical SubQ peptide profile.
- Sleep changes — Vivid dreaming is frequently reported; consistent with proposed pineal/melatonin mechanism. Usually welcomed.
- Mood / affect — Occasional mild mood elevation reported. Rare reports of mild initial lethargy in the first 1–3 doses.
- Cancer / tumor growth concerns (theoretical but mixed direction) — Telomerase activation is theoretically pro-proliferative and carries a theoretical cancer concern. However, the Anisimov SHR mouse data showed reduced spontaneous tumor incidence rather than increased, and the Khavinson clinical cohort did not show elevated cancer mortality. The direction of the signal in humans is uncertain; mainstream oncologic caution in active-cancer patients is still warranted.
- Hormonal effects — Minimal documented endocrine impact; melatonin restoration in aged individuals is the best-characterized hormonal effect.
- Allergic reactions (rare) — Standard peptide immunogenicity risk; rare in practice.
- Drug interactions — Largely unstudied. Theoretical interactions with melatonergic drugs (agomelatine, ramelteon) and with circadian-modulating light therapy.
- Pregnancy / lactation — Not studied; avoid.
- Active malignancy — Relative contraindication given theoretical telomerase-proliferative concern. Discuss with oncology before initiating.
- Purity / sourcing — Gray-market tetrapeptide is straightforward to synthesize and typically less prone to purity problems than larger peptides, but third-party COAs are the floor. Russian pharmacy imports of authentic Khavinson-origin Epithalon are the quality benchmark.
- WADA status — Not specifically listed on the WADA Prohibited List. Athletes should assume broad umbrella categories may apply.
- FDA status — Not approved; not a controlled substance. Gray-market import for personal use exists in a regulatory gray area.
Bloodwork & Monitoring
Formal Epithalon monitoring guidelines do not exist. Sensible monitoring for long-term longevity protocols:
- Baseline CMP / CBC — Standard; repeat annually if courses continue.
- Fasting insulin / HbA1c — Longevity markers; baseline and annually.
- hsCRP — Inflammation baseline; relevant for the Khavinson-framework "aging as inflammatory state" hypothesis.
- Lipid panel — Standard cardiovascular tracking.
- Vitamin D, B12, homocysteine — Baseline; relevant for overall longevity protocol.
- Telomere length — Commercial telomere assays (Life Length T/C, TeloYears) give semi-quantitative data. Variability is high and short-course sensitivity is limited.
- Biological age (methylation clocks) — DunedinPACE, GrimAge, PhenoAge via TruDiagnostic or similar. Expensive but increasingly mainstream as a longevity-protocol outcome measure.
- Age-appropriate cancer screening — Colonoscopy, mammography, PSA, derm. Not Epithalon-specific but baseline-prudent before long-term peptide protocols.
- Sleep tracking — Objective sleep data (HRV, sleep stages) capture Epithalon's most consistent acute signal.
Commonly Stacked With
Thymus-derived bioregulator. The Khavinson cohort's 4.1× mortality reduction was specifically in the combined Epithalon + Thymalin + annual redosing protocol. The canonical Khavinson combination.
Khavinson tripeptide with cognitive-longevity focus. Commonly alternated with or combined with Epithalon for layered bioregulator effect.
Low-dose melatonin (0.3–3 mg)
Complements Epithalon's proposed pineal/melatonin mechanism if endogenous melatonin is inadequate. Use modest doses — chronic high-dose melatonin may blunt endogenous rhythm.
Different mechanism (mitochondrial substrate vs telomere/transcriptional). Complementary longevity stacking; no known antagonistic interactions.
Gene-expression-modulating tripeptide with broad transcriptomic effects. Layered longevity protocol with Epithalon; different mechanism of action.
Resveratrol / pterostilbene
SIRT1 activators for complementary longevity pathway support. Non-peptide; minimal interaction concern.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
Epithalon is not approved by the FDA, EMA, or any major Western regulator. It is in clinical use in Russia as part of the Khavinson bioregulator framework for geriatric practice and has 30+ years of Russian clinical experience.
Epithalon is not currently on the FDA Category 2 Bulk Drug Substances list. The February 2026 HHS peptide reclassification announcement targeted a specific subset of previously Category 2 peptides; public reporting has not specifically included Epithalon. Compounding of Epithalon by US 503A/503B pharmacies is not legally clear.
Epithalon is not specifically named on the WADA Prohibited List. Athletes should consult their federation given that telomerase-activating and metabolic-modulating compounds can fall under broad umbrella categories.
Epithalon is not a DEA-scheduled controlled substance in the United States. Community availability is through research-chemical suppliers or international pharmacy import. Personal-use import is in a gray area.
Cost & Access
Epithalon (Epitalon, AEDG) is not approved for human use in the United States, the EU, or any major Western jurisdiction. It is available through research suppliers for laboratory research purposes only.
U.S. compounding pharmacies cannot legally compound Epithalon under current FDA bulk-substance rules — it has no FDA-approved reference product. Research-chemical vendors (Novoprolabs, Peptide Sciences, BioLongevity Labs, Core Peptides, and similar) sell lyophilized Epithalon in 10 mg or 50 mg vials. A typical community Khavinson protocol (5–10 mg/day SubQ for 10–20 days, repeated 1–2× per year) consumes 50–200 mg per course.
Russian and Belarusian pharmacies sell Epithalamin (the injectable pineal polypeptide complex Epithalon was derived from) and, in some markets, AEDG-specific formulations through the Peptide Bioregulators framework. Personal-use import to the United States exists in a legal gray area; bulk import is prosecuted.
Epithalon is not currently among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. Absent a sponsor advancing Epithalon through the U.S. NDA pathway (highly unlikely given the 30-year Khavinson publication history without Western regulatory engagement) or explicit inclusion in a future FDA bulk-substance action, Epithalon will remain in the research-only category for the foreseeable future.
Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching Epithalon often also look at these:
N-acetylated epithalon analogue with improved bioavailability and longer half-life.
Khavinson dipeptide (Lys-Glu). Immune/longevity-oriented short-peptide bioregulator.
Khavinson tetrapeptide (Lys-Glu-Asp-Ala). Liver-oriented short peptide bioregulator.
Khavinson tripeptide (Ala-Glu-Asp). Cartilage and joint-oriented short peptide bioregulator.
Key References
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682.
- Anisimov VN, Khavinson VKh, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID: 14501183.
- Al-Dulaimi MS, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. 2025. PMID: 40908429. PMC12411320. (Modern Western-lab replication of the central telomerase-activation claim.)
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. (266-patient elderly mortality cohort.)
- Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12370707. (Comprehensive Khavinson monograph.)
- Khavinson VKh, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin'kova NS. Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bull Exp Biol Med. 2017;164(1):41-43.
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997.
- Khavinson VKh, Solov'ev AY, Zhilinskii DV, Shatayev VS, Morozov VG. Effect of epithalon on activity of antioxidant enzymes. Bull Exp Biol Med. 2011;151(4):472-473.
- Kossoy G, Zandbank J, Tendler E, Anisimov V, Khavinson V, Popovich I, Zabezhinski M, Zusman I, Ben-Hur H. Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa. Int J Mol Med. 2003;12(4):473-477. PMID: 12964019.
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506.
- Labunets IF, Butenko GM, Dragunova VA, Magdich LV, Khavinson VKh. Effect of epithalamin, thymalin, and tocopherol on age-associated involution of the pineal gland in rats. Bull Exp Biol Med. 2004;137(5):510-512.
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector Epitalamin: effects on vascular endothelial function in elderly patients. Adv Gerontol. 2010;23(3):440-446.
- Khavinson VKh, Linkova NS, Tarnovskaia SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292.
- Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. (Comprehensive 40-year review.)
- Kozina LS, Arutjunyan AV, Khavinson VKh. Antioxidant properties of geroprotective peptides of the pineal gland. Arch Gerontol Geriatr. 2007;44 Suppl 1:213-216.
- Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mikhailova N, Petukhov M. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2021;14(6):515.
- Khavinson VKh, Sibarov DA, Tsai PY, Adushkin BV, Ryzhak GA. Short peptides stimulate serotonin release and attenuate hyperexcitation in the hippocampus. Bull Exp Biol Med. 2017;163(4):539-541.
- Khavinson V, Popovich I. Short peptides regulate gene expression, protein synthesis and enhance life span. In: Understanding the Aging Process and Age-Related Diseases. Academic Press; 2017.
Last updated: April 2026 | Profile authored by Kalios Peptides research team